CHF 4.12 close: DocMorris AG (DOCM.SW, SIX) ahead of earnings 18 Mar 2026: key cues

DOCM.SW stock closed at CHF 4.12 on 18 Mar 2026 as DocMorris AG (DOCM.SW) heads into an earnings release tomorrow. Traders will watch revenue mix, margins and cash flow after a year-to-date slide of -28.41%. Volume rose to 333,914 shares versus an average of 288,401, signalling investor attention ahead of results. Key data points to track in the earnings report include EPS of -4.58, current guidance commentary, and any updates on the company’s Swiss and international pharmacy operations. For company details see the DocMorris investor site source and SIX exchange information source.

Earnings context and expectations for DOCM.SW stock

DocMorris AG reports after the close and DOCM.SW stock trades at CHF 4.12; the market is focused on profitability signals and cash burn. The company shows EPS of -4.58 and a negative PE ratio of -0.94, so investors will weigh margin recovery and cost control. Recent seasonal trends and year-over-year revenue growth of 4.91% (FY 2024) set a low bar for upside but management commentary on prescription volumes matters.

Recent price action and valuation for DOCM.SW stock

DOCM.SW stock hit a day high of CHF 4.30 and a low of CHF 4.11 on 18 Mar 2026, with a year high of CHF 24.90 and a year low of CHF 4.01. Market cap stands at CHF 208,393,554.00 and shares outstanding are 48,599,243.00. Valuation ratios show price-to-sales 0.20 and price-to-book 0.26, suggesting the market prices deep discount to book value while the stock works through operational recovery.

Meyka AI grade and DOCM.SW stock forecast

Meyka AI rates DOCM.SW with a score out of 100: Meyka AI rates DOCM.SW with a score of 63.72 / 100, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a near-term (quarter) model target of CHF 5.56 and a 12‑month model target of CHF 6.18. Compared with the current price of CHF 4.12, that implies a model-based upside of 34.95% to CHF 5.56 and 50.00% to CHF 6.18. Forecasts are model-based projections and not guarantees.

Operational and financial metrics that matter for DOCM.SW stock

Key balance-sheet metrics support liquidity: cash per share is CHF 7.89, book value per share is CHF 16.47 and current ratio is 3.25, which cushions near-term obligations. Free cash flow per share is negative at -CHF 2.48, and operating cash flow per share is -CHF 2.42, highlighting ongoing cash conversion weakness. Debt-to-equity is 0.65 and interest coverage is 1.24, which keeps financing risk visible but not acute.

Technical setup and trading signals for DOCM.SW stock

Momentum indicators are oversold: RSI 18.09, MFI 15.39, and Williams %R -100.00. The 50-day average is CHF 5.55 and the 200-day average is CHF 6.18, both well above the current price and signalling a downtrend. Relatively high intraday volatility shows earnings can move price quickly; today’s relative volume of 1.53 and on‑balance volume trending negative suggest sellers dominated prior sessions.

Risks and catalysts for DOCM.SW stock

Near-term risk to DOCM.SW stock comes from continued margin pressure, negative EPS, and a low earnings history—EPS is -4.58 and net margin is -11.38%. Catalysts that could re-rate the stock include upward guidance, evidence of margin improvement, or positive free cash flow conversion. Sector context: healthcare peers trade at much higher P/E ratios, so DocMorris must show sustainable profit recovery to close the valuation gap.

Final Thoughts

DocMorris AG (DOCM.SW) enters its next earnings release with the stock at CHF 4.12 on 18 Mar 2026 and clear investor focus on profit recovery and cash flow. Operational liquidity looks reasonable—cash per share CHF 7.89 and current ratio 3.25—but negative EPS -4.58 and weak free cash flow maintain execution risk. Meyka AI’s model projects CHF 5.56 as a near-term target and CHF 6.18 at 12 months, implying upside of 34.95% and 50.00% respectively versus CHF 4.12. Technicals are oversold, which may magnify the stock’s reaction to any positive surprise. Our view frames this as a data-driven earnings play: a positive beat and improved guidance could trigger a multi-week recovery, while any guidance miss would likely put further pressure on the share price. These notes are analysis, not investment advice, and Meyka AI — an AI-powered market analysis platform — provides model-based forecasts that are not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.